# US HIV Diagnostics Market > US HIV Diagnostics Market Research Report By Test Type (Antibody Tests, Antigen Tests, Nucleic Acid Tests), By End User (Hospitals, Diagnostic Laboratories, Home Care Settings), By Product Type (Tests Kits, Instruments, Software) and By Technology (Elisa, Rapid Testing, Polymerase Chain Reaction) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.05% - **2024:** $ 690.48 Million - **2035:** $ 1,068.59 Million - **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Becton Dickinson and Company (US), Hologic Inc. (US), Cepheid (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US) **Report ID:** MRFR/Pharma/15130-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-hiv-diagnostics-market-16658 --- ## Market Summary ## **US HIV Diagnostics Market Overview** As per MRFR analysis, the US HIV Diagnostics Market Size was estimated at 744.06 (USD Million) in 2023. The US HIV Diagnostics Market Industry is expected to grow from 774.2 (USD Million) in 2024 to 1,249.5 (USD Million) by 2035. The US HIV Diagnostics Market CAGR (growth rate) is expected to be around 4.448% during the forecast period (2025 - 2035). ### **Key Trends Shaping the Market** The US HIV Diagnostics Market is shaped by several important trends that reflect the ongoing evolution in disease management and public health strategies. A key market driver is the increased awareness and education regarding HIV, which has led to a rise in testing and early diagnosis. Government initiatives and public health campaigns are encouraging more individuals to get tested, particularly among high-risk populations. This has created a greater demand for rapid diagnostic tests that provide quicker results. Moreover, the shift towards personalized healthcare is presenting opportunities to innovate within the diagnostics space. New technologies, such as point-of-care testing, offer convenience and increased accessibility to patients who may otherwise remain undiagnosed. The adoption of these technologies aligns with efforts to improve the overall efficiency of HIV prevention and treatment services in the US. In recent times, there has also been a noticeable trend towards the integration of HIV diagnostics with other sexually transmitted infection (STI) testing. This holistic approach not only streamlines the diagnostic process but also raises awareness about the interconnectedness of various STIs, further promoting public health. Additionally, the role of telemedicine has expanded, allowing for remote consultations and follow-up care, thus enhancing access to diagnostic services, especially in underserved areas. This trend reflects the ongoing need for innovative solutions that address health disparities within the US. Overall, these trends indicate a dynamic market that is increasingly focused on early detection, accessibility, and comprehensive care in managing and preventing HIV. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US HIV Diagnostics Market Drivers** ### **Increasing Awareness and Education About HIV** In the United States, there has been a significant push for HIV prevention and education through various programs and initiatives. Organizations such as the Centers for Disease Control and Prevention (CDC) have amplified awareness campaigns significantly since the early 2000s, leading to improved knowledge of HIV transmission and the importance of regular testing. The CDC reported that approximately 1.2 million people in the US are living with HIV, with around 14% of them being unaware of their infection status. This heightened awareness directly correlates with increased testing and diagnostics, driving growth in the US [HIV Diagnostics Market](../../../reports/hiv-diagnostics-market-9757) Industry. Moreover, increasing public transportation access and outreach services have facilitated easier testing, thus positively impacting overall market growth. For instance, public health initiatives in urban areas, coupled with community-based outreach programs, have led to a notable increase in HIV testing uptake by about 30% from 2015 to 2020. Such initiatives not only bolster the demand for HIV diagnostics but also contribute to health equity efforts among diverse populations. ### **Advancements in Diagnostic Technology** Advancements in diagnostic technology have played a crucial role in shaping the US HIV Diagnostics Market Industry. Innovations such as point-of-care testing and self-testing kits have significantly enhanced the accessibility and efficiency of HIV diagnosis. The Food and Drug Administration (FDA) has approved several rapid diagnostic tests which provide results in as little as 20 minutes, facilitating timely interventions. Reports indicate that the adoption of at-home HIV testing kits has surged by approximately 45% from 2017 to 2021, reflecting a shift in patient preferences towards more convenient and private testing options. Companies like AbbVie and Roche have introduced user-friendly diagnostic tools that can be utilized at home, driving up the demand within the market. ### **Rising Government Initiatives for HIV Prevention** The US government's commitment to combating HIV through various strategic initiatives considerably supports the US HIV Diagnostics Market Industry. The Ending the HIV Epidemic plan, launched by the Department of Health and Human Services (HHS) in 2019, aims to reduce HIV infections by 75% by 2025 through increased testing, treatment, and prevention efforts. This initiative allocated substantial funding to support HIV testing programs, thereby boosting the market. Data show that over 200 million USD was invested in fiscal year 2020 alone, contributing to a 20% increase in HIV testing in targeted areas. With state health departments and community-based organizations receiving grants to expand testing services, the accessibility of diagnostic solutions is expected to grow, propelling the market forward. ### **Increasing Number of High-Risk Populations** The prevalence of HIV remains notably high among specific demographic groups in the US, thereby driving the demand for HIV diagnostic solutions. Reports indicate that men who have sex with men (MSM) represent approximately 70% of new HIV diagnoses. Additionally, the racial and ethnic minorities, including African Americans and Latinos, have faced disproportionate rates of HIV infection, further underscoring the need for targeted testing among these populations. The ongoing prevalence of HIV in these groups, combined with a rise in new diagnoses among young adults aged 13 to 24, necessitates innovative diagnostic solutions to effectively manage and understand the disease's dynamics. Advocacy groups and organizations, such as the American Academy of HIV Medicine, are vigorously working towards addressing these disparities, ensuring that these high-risk populations have access to comprehensive testing and treatment options, thus contributing to the growth of the US HIV Diagnostics Market Industry. ## **US HIV Diagnostics Market Segment Insights** ### **HIV Diagnostics Market Test Type Insights** The US HIV Diagnostics Market, particularly focusing on the Test Type segment, plays a critical role in the healthcare landscape. The market is primarily characterized by three main testing methodologies Antibody Tests, Antigen Tests, and Nucleic Acid Tests. Each of these tests has unique functionality and significance in diagnosing HIV, shaping the diagnostic landscape. Antibody Tests are widely utilized, as they measure the body's immune response to HIV, showcasing their importance in large-scale screening programs due to their ease of use and cost-effectiveness, thus facilitating early diagnosis. On the other hand, Antigen Tests provide the advantage of detecting viral proteins in the early stages of HIV infection, making them vital in acute diagnosis. They are increasingly gaining traction among healthcare providers aiming for prompt treatment initiation. Nucleic Acid Tests stand out for their ability to identify HIV at very low levels, proving significant, especially in high-risk populations where early interventions can dramatically improve health outcomes. This Test Type segmentation reflects a variety of healthcare needs, driven by factors such as rising infection rates and the push for widespread testing. The importance of early detection is amplified by the Centers for Disease Control and Prevention statistics showing that about 1.2 million people in the U.S. are living with HIV, with nearly 13% unaware of their infection. This highlights a crucial opportunity for enhancing testing methods and accessibility across diverse populations. Consequently, the overall growth in the US HIV Diagnostics Market is driven by the demand for accurate and timely diagnostic tests that cater to a variety of clinical scenarios and patient needs, fostering a comprehensive approach to HIV management and care. With ongoing advancements in technology and increasing public health awareness, the Test Type segment is projected to continue evolving, making significant contributions to the overall efficacy of HIV diagnosis in the United States. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **HIV Diagnostics Market End User Insights** The End User segment of the US HIV Diagnostics Market plays a crucial role in the delivery of essential healthcare services. Hospitals are significant players, providing comprehensive HIV testing and management services, which are vital for early diagnosis and treatment. These facilities possess the necessary infrastructure, trained personnel, and state-of-the-art technology to support accurate testing and patient care. Diagnostic Laboratories also hold a considerable position in the US HIV Diagnostics Market, as they specialize in performing a wide range of laboratory tests, enhancing the efficiency and accuracy of HIV diagnostics. Their ability to provide rapid testing solutions meets the increasing demand for timely results. Furthermore, Home Care Settings are gaining traction, particularly in the wake of the COVID-19 pandemic, as they provide a convenient and accessible means for individuals to receive testing in the comfort of their homes. This shift is driven by an increase in awareness and acceptance of HIV testing, underscoring the importance of these settings in promoting public health. Overall, the US HIV Diagnostics Market segmentation illustrates a multi-faceted approach to addressing HIV testing needs across diverse environments, encouraging early detection and reducing transmission rates. ### **HIV Diagnostics Market Product Type Insights** The US HIV Diagnostics Market, particularly in the realm of Product Type, comprises critical components such as Test Kits, Instruments, and Software, each holding significant importance in the ongoing battle against HIV. Test Kits dominate the landscape due to their wide application in both professional and at-home testing, facilitating early diagnosis and timely treatment. Instruments play a vital role in enhancing the accuracy and efficiency of diagnostic procedures, contributing to the reliability of results in clinical settings. Meanwhile, Software is increasingly pivotal in streamlining data management, ensuring compliance, and enabling integration with health information systems, which is essential for tracking and reporting HIV-related data effectively. The ongoing trend emphasizing preventive healthcare and rapid testing solutions further fuels the demand across these product types, allowing for improved patient outcomes and public health strategies. The market is influenced by growth drivers including increasing healthcare awareness and rising government initiatives aimed at reducing HIV transmission rates in the US. Challenges such as regulatory hurdles and the need for continuous innovation in testing methodologies remain prevalent, but the evolution toward more advanced diagnostic technologies offers numerous opportunities to innovate within the market. ### **HIV Diagnostics Market Technology Insights** The Technology segment of the US HIV Diagnostics Market plays a critical role in enhancing the accuracy and speed of HIV detection. Among its components, Enzyme-Linked Immunosorbent Assay (ELISA) serves as a foundational method for diagnosing HIV infections, primarily due to its high sensitivity and reliability, establishing it as a key player in routine screenings. Rapid Testing, on the other hand, has gained substantial importance in the US healthcare system as it allows for immediate results and facilitates timely treatment decisions, which is essential in controlling the spread of HIV. Moreover, Polymerase Chain Reaction (PCR) technology is significant for its capacity to detect viral RNA, making it indispensable in monitoring viral loads and diagnosing acute infections. These advancements contribute to ongoing initiatives aimed at increasing testing accessibility across diverse populations in the US, addressing both public health needs and the growing demand for innovative diagnostic solutions. Notably, the integration of these technologies is essential in facilitating early HIV detection and treatment engagement, ultimately aiming to reduce transmission rates and improve health outcomes in affected communities. ## **US HIV Diagnostics Market Key Players and Competitive Insights** The competitive landscape of the US HIV diagnostics market is marked by continuous innovation and strategic developments aimed at improving detection, monitoring, and prevention of HIV. With increasing awareness about HIV testing and diagnosis, a variety of diagnostic methods have been introduced, including rapid tests, viral load assays, and point-of-care testing solutions. As market players strive for a competitive edge, factors such as accuracy, reliability, speed of results, and ease of use play a significant role in influencing physician and patient choices. The emphasis on early diagnosis and access to treatment has pushed companies to invest in advanced technologies, enhancing the capabilities of diagnostic solutions tailored to meet the unique needs of healthcare providers and patients alike. Diagnostics for All is recognized as a player actively seeking to establish a strong presence within the US HIV diagnostics market through its innovative and accessible solutions. The company focuses on developing diagnostics that not only provide accurate results but are also cost-effective and easy to use in various healthcare settings. Their strengths lie in their commitment to making diagnostic testing available to underserved populations, thereby contributing to increased testing rates and improved health outcomes. By being dedicated to research and development, Diagnostics for All has built a reputation for enhancing public health awareness about HIV, driving awareness for the importance of regular testing, and aligning with initiatives aiming for the elimination of HIV transmission in the longer term. Hologic stands out in the US HIV diagnostics market with a comprehensive portfolio that includes leading-edge technologies for HIV diagnostics. Hologic's key products and services encompass a range of molecular and immunoassay testing solutions designed for accurate detection of HIV infections. Their robust market presence is complemented by strategic partnerships, mergers, and acquisitions aimed at expanding their technological capabilities and market reach. Through these efforts, Hologic has fortified its standing in the industry, leveraging advanced platforms and strong distribution networks to broaden their accessibility in both clinical and laboratory settings. The company's focus on innovation supports their goal of improving patient care and outcomes, solidifying their role as a significant contributor to the ongoing fight against HIV in the United States. ### **Key Companies in the US HIV Diagnostics Market Include** ## **US HIV Diagnostics Market Industry Developments** The US HIV Diagnostics Market has witnessed various developments recently, with companies like Abbott Laboratories and Roche Holding focusing on enhancing testing technologies and ensuring broader accessibility. Notably, Abbott Laboratories launched its new HIV test in September 2023, designed to increase diagnosis rates, particularly among underserved populations. In addition, BioRad Laboratories has been working on innovative solutions to improve laboratory testing efficiency. The market has experienced significant growth, with valuations of enterprises like Hologic and Quidel Corporation showing robust upward trends due to increased federal funding for HIV testing initiatives. There were no recent mergers or acquisitions reported among key players in the US HIV Diagnostics Market. In the last two to three years, significant advancements, such as the FDA's approval of rapid testing devices, have shaped the market dynamics, encouraging competitive innovation among major players like Grifols and Siemens Healthineers. As the government continues to emphasize HIV awareness and testing, the overall landscape remains optimistic, reflecting an ongoing commitment to eradicating the epidemic by improving diagnostic capabilities across the United States. ## **US HIV Diagnostics Market Segmentation Insights** ### **HIV Diagnostics Market Test Type Outlook** ### **HIV Diagnostics Market End User Outlook** ### **HIV Diagnostics Market Product Type Outlook** ### **HIV Diagnostics Market Technology Outlook** ## Market Drivers ### Rising Prevalence of HIV The increasing prevalence of HIV in the US is a critical driver for the HIV Diagnostics Market. According to the Centers for Disease Control and Prevention (CDC), approximately 1.2 million people in the US are living with HIV, with around 14% unaware of their infection. This substantial number underscores the necessity for effective diagnostic tools to identify and manage the disease. The growing population of individuals living with HIV necessitates enhanced testing capabilities, thereby propelling the demand for innovative diagnostic solutions. Furthermore, the rising incidence rates among specific demographics, particularly among young adults and marginalized communities, highlight the urgent need for targeted diagnostic strategies. As awareness of HIV continues to grow, the hiv diagnostics market is likely to expand, driven by the need for timely and accurate testing to facilitate early intervention and treatment. ### Emergence of Point-of-Care Testing The emergence of point-of-care (POC) testing is transforming the HIV Diagnostics Market by providing rapid and accessible testing options. POC tests allow for immediate results, which is crucial for timely diagnosis and treatment initiation. This shift towards decentralized testing is particularly beneficial in rural and underserved areas where access to traditional laboratory facilities may be limited. The convenience and speed of POC testing can significantly enhance patient engagement and adherence to treatment protocols. According to recent data, the POC testing segment is expected to witness substantial growth, potentially reaching a market value of $1 billion by 2026. This trend indicates a growing recognition of the importance of accessible diagnostic solutions in managing HIV. As healthcare providers increasingly adopt POC technologies, the hiv diagnostics market is likely to expand, driven by the demand for efficient and user-friendly testing methods. ### Government Initiatives and Funding Government initiatives and funding play a pivotal role in shaping the HIV Diagnostics Market. The US government has implemented various programs aimed at increasing access to HIV testing and treatment. For instance, the Ryan White HIV/AIDS Program provides essential services to individuals living with HIV, including diagnostic testing. Additionally, the CDC allocates substantial funding for HIV prevention and testing initiatives, which directly impacts the availability and development of diagnostic technologies. In recent years, federal funding for HIV-related programs has seen an increase, reflecting a commitment to combat the epidemic. This financial support not only enhances testing infrastructure but also encourages innovation within the hiv diagnostics market. As government policies continue to evolve, they are likely to foster an environment conducive to the growth of diagnostic solutions, ultimately improving health outcomes for those affected by HIV. ### Growing Demand for Home Testing Kits The growing demand for home testing kits is reshaping the HIV Diagnostics Market by offering individuals greater privacy and convenience. As awareness of HIV increases, more people are seeking accessible testing options that can be performed in the comfort of their own homes. Home testing kits provide a discreet alternative to traditional testing methods, which may deter some individuals from seeking necessary care. Recent surveys indicate that nearly 50% of individuals would prefer to use home testing kits for HIV screening. This trend is likely to drive innovation within the hiv diagnostics market, as manufacturers develop user-friendly and reliable home testing solutions. The convenience of home testing may also lead to increased testing rates, ultimately contributing to better public health outcomes. As the market adapts to this growing demand, the availability and variety of home testing kits are expected to expand, further influencing the dynamics of the hiv diagnostics market. ### Advancements in Molecular Diagnostics Advancements in molecular diagnostics are significantly influencing the HIV Diagnostics Market. Technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) are enhancing the accuracy and sensitivity of HIV testing. These innovations allow for the detection of the virus at lower levels, enabling earlier diagnosis and better monitoring of treatment efficacy. The increasing adoption of molecular diagnostic techniques is expected to drive market growth, as healthcare providers seek more reliable testing options. Recent estimates suggest that the molecular diagnostics segment could account for over 30% of the total hiv diagnostics market by 2027. This shift towards more sophisticated testing methods reflects a broader trend in healthcare towards precision medicine. As molecular diagnostics continue to evolve, they are likely to play a crucial role in the future of the hiv diagnostics market, improving patient outcomes through enhanced testing capabilities. ## Future Outlook The [HIV Diagnostics Market](https://www.marketresearchfuture.com/reports/hiv-diagnostics-market-9757) is projected to grow at 4.05% CAGR from 2025 to 2035, driven by technological advancements, increased awareness, and enhanced testing accessibility. **New opportunities:** - Development of mobile testing units for remote areas - Integration of AI for rapid diagnostic analysis - Expansion of telehealth services for HIV testing consultations By 2035, the market is expected to achieve substantial growth, reflecting advancements in diagnostics and increased healthcare access. ## Segment Insights ### By Test Type: Antibody Tests (Largest) vs. Antigen Tests (Fastest-Growing) In the US HIV Diagnostics Market, the distribution of market share among test types reveals a competitive landscape. Antibody tests hold the largest share, widely recognized for their efficacy in detecting HIV antibodies. They have established themselves as the preferred option for many healthcare providers due to their reliability and widespread availability. Conversely, antigen tests are rapidly gaining traction and are becoming preferred due to their ability to detect active infections, providing timely results that are crucial in patient management. Growth trends in the US hiv diagnostics market signal a shift towards more innovative testing methodologies. Antigen tests are emerging as the fastest-growing segment, driven by advancements in technology that enhance product reliability and ease of use. Factors such as increased awareness of HIV testing and a push for more accessible healthcare also contribute significantly to the upward growth trajectory of both antibody and antigen tests, reflecting changing consumer preferences and healthcare policies. Antibody Tests (Dominant) vs. Antigen Tests (Emerging) Antibody tests continue to dominate the US hiv diagnostics market, owing to their established presence and extensive use in clinical settings. Their primary strength lies in their accuracy and cost-effectiveness, making them a staple in HIV screening programs. On the other hand, antigen tests are the emerging category, characterized by their ability to detect the HIV virus earlier than antibody tests. This feature presents a significant advantage, especially in early detection scenarios. As healthcare systems prioritize rapid and efficient diagnostic solutions, the appeal of antigen tests is growing, supported by innovations that improve their usability in various settings, including home testing. ### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing) In the US HIV Diagnostics Market, the distribution of market share among the end user segments reveals that hospitals hold the largest share, serving as the primary point for patient diagnosis and management. Conversely, diagnostic laboratories are rapidly gaining ground, supported by advancements in technology and a rising demand for specialized testing options. Home care settings, while an important segment, currently represent a smaller portion of the market compared to hospitals and diagnostic labs. The growth trends in the end user segment are driven by various factors, including increasing awareness of HIV testing, advancements in diagnostic technology, and the shift towards decentralized healthcare. As more individuals seek convenient testing options, home care settings are beginning to emerge as potential growth areas. Diagnostic laboratories are expanding their capabilities to cater to this demand, establishing themselves as key players for the future. Hospitals: Dominant vs. Home Care Settings: Emerging Hospitals remain the dominant end user in the US hiv diagnostics market, benefiting from comprehensive resources and access to a wide array of diagnostic tools. Their established infrastructure supports the timely and accurate diagnosis of HIV, making them essential in patient care. On the other hand, home care settings are positioned as an emerging segment, driven by a growing need for convenience and privacy in testing. These settings offer patients the ability to undergo testing in their own environment, potentially increasing the overall number of individuals willing to get tested. The trend towards telehealth and home-based care solutions enhances the attractiveness of this emerging segment, indicating a shift in patient preferences. ### By Product Type: Test Kits (Largest) vs. Instruments (Fastest-Growing) In the US HIV Diagnostics Market, Test Kits hold the largest share within the product type segment, indicating their widespread preference among healthcare providers and patients for rapid and reliable testing solutions. This segment is favored due to its ease of use, accessibility, and the ability to deliver quick results, which are crucial in managing and controlling HIV transmission effectively. On the other hand, the Instruments segment is emerging as the fastest-growing category, driven by advancements in technology and automation in diagnostic processes. The integration of advanced features in diagnostic instruments enhances precision and efficiency, making them increasingly attractive for clinical laboratories. The push towards more comprehensive testing approaches and real-time monitoring is further fueling demand for sophisticated diagnostic instruments. Test Kits: Dominant vs. Instruments: Emerging Test Kits are characterized by their user-friendly nature, allowing for self-administration and immediate results, thereby streamlining the testing process. They are particularly dominant in settings where quick diagnosis is essential, such as urgent care centers and during outreach programs. In contrast, Instruments are becoming an emerging force in the market, showcasing innovative technologies that offer enhanced sensitivity and specificity. These devices often accompany laboratory settings where bulk testing is conducted, and errors must be minimized. The distinction between the two highlights a market that values both immediate results and advanced technological capabilities. ### By Technology: Elisa (Largest) vs. Rapid Testing (Fastest-Growing) In the US HIV Diagnostics Market, Elisa testing holds the largest share among the various technologies, primarily due to its reliability and established usage in clinical settings. Rapid testing follows, capturing a significant portion of the market thanks to its ability to deliver quick results and facilitate immediate treatment decisions, although its share is smaller compared to Elisa. The Polymerase Chain Reaction (PCR) method, while critical for accurate viral load measurements, remains less common compared to these other two methods due to its higher complexity and cost. The growth trends in this segment are driven by increasing healthcare initiatives aimed at expanding testing access and early diagnosis. Rapid testing is emerging as the fastest-growing segment, bolstered by technological advancements and heightened demand for immediate results. Meanwhile, Elisa technology continues to thrive due to its widespread acceptance and integration in existing healthcare frameworks, ensuring its dominant position for the foreseeable future. Technology: Elisa (Dominant) vs. Rapid Testing (Emerging) Elisa testing is widely recognized as the dominant technology in the US hiv diagnostics market. It is highly regarded for its accuracy and efficacy, making it a go-to method for confirming HIV infections. The method has a long-standing presence in laboratories, which contributes to its strong market position. In contrast, rapid testing is an emerging technology that is gaining traction due to its user-friendly design and swift results, often available within minutes. This aspect makes rapid testing particularly appealing in urgent care settings and among populations with limited access to healthcare facilities. As the demand for faster diagnostic tools increases, rapid testing is expected to expand its share and relevance within the market. ## Competitive Benchmarking The HIV diagnostics market is characterized by a dynamic competitive landscape, driven by technological advancements, increasing awareness, and the need for rapid testing solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing, which aligns with the growing demand for rapid and accurate diagnostics. Roche Diagnostics (CH) emphasizes partnerships and collaborations to expand its product offerings, while Thermo Fisher Scientific (US) is investing in digital transformation to streamline operations and improve customer engagement. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological innovation and strategic partnerships. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger companies leverage their resources to capture significant market share. The collective influence of these key players shapes the market dynamics, fostering an environment where innovation and strategic positioning are paramount. In October 2025, Abbott Laboratories (US) announced the launch of a new rapid HIV test that provides results in under 15 minutes, significantly reducing the time required for diagnosis. This strategic move is likely to enhance Abbott's competitive edge by addressing the urgent need for quick testing solutions, particularly in underserved regions. The introduction of this product may also align with public health initiatives aimed at increasing testing rates and improving patient outcomes. In September 2025, Roche Diagnostics (CH) expanded its collaboration with a leading telehealth provider to integrate HIV testing into remote healthcare services. This partnership is strategically important as it reflects the growing trend towards telemedicine, allowing Roche to reach a broader patient base and enhance accessibility to HIV diagnostics. By leveraging telehealth, Roche is likely to position itself as a leader in innovative healthcare solutions, catering to the evolving needs of patients and healthcare providers. In August 2025, Thermo Fisher Scientific (US) unveiled a new AI-driven analytics platform designed to enhance the accuracy of HIV diagnostics. This platform utilizes machine learning algorithms to analyze test results and provide actionable insights for healthcare professionals. The strategic importance of this development lies in its potential to improve diagnostic accuracy and streamline workflows, thereby enhancing patient care. By integrating AI into its offerings, Thermo Fisher is likely to differentiate itself in a competitive market increasingly focused on technology-driven solutions. As of November 2025, current trends in the HIV diagnostics market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly vital, as companies seek to enhance their capabilities and expand their reach. The competitive landscape is shifting from traditional price-based competition to a focus on innovation, technology, and supply chain reliability. This evolution suggests that companies that prioritize these aspects will likely achieve a sustainable competitive advantage in the future. ## Recent News & Developments The US HIV Diagnostics Market has witnessed various developments recently, with companies like Abbott Laboratories and Roche Holding focusing on enhancing testing technologies and ensuring broader accessibility. Notably, Abbott Laboratories launched its new HIV test in September 2023, designed to increase diagnosis rates, particularly among underserved populations. In addition, BioRad Laboratories has been working on innovative solutions to improve laboratory testing efficiency. The market has experienced significant growth, with valuations of enterprises like Hologic and Quidel Corporation showing robust upward trends due to increased federal funding for HIV testing initiatives. There were no recent mergers or acquisitions reported among key players in the US HIV Diagnostics Market. In the last two to three years, significant advancements, such as the FDA's approval of rapid testing devices, have shaped the market dynamics, encouraging competitive innovation among major players like Grifols and Siemens Healthineers. As the government continues to emphasize HIV awareness and testing, the overall landscape remains optimistic, reflecting an ongoing commitment to eradicating the epidemic by improving diagnostic capabilities across the United States. ## Report Scope | US MARKET SIZE 2024 | 690.48(USD Million) | | --- | --- | | US MARKET SIZE 2025 | 718.44(USD Million) | | US MARKET SIZE 2035 | 1068.59(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.05% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Becton Dickinson and Company (US), Hologic Inc. (US), Cepheid (US), Bio-Rad Laboratories (US), Ortho Clinical Diagnostics (US) | | Segments Covered | Test Type, End User, Product Type, Technology | | Key Market Opportunities In US | Integration of advanced molecular diagnostics enhances early detection and treatment options in the hiv diagnostics market. | | Key Market Dynamics In US | Technological advancements and regulatory changes drive innovation in the HIV diagnostics market, enhancing testing accuracy and accessibility. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US HIV diagnostics market in 2024?** A: The overall market valuation was $690.48 Million in 2024. **Q: What is the projected market valuation for the US HIV diagnostics market by 2035?** A: The projected valuation for 2035 is $1,068.59 Million. **Q: What is the expected CAGR for the US HIV diagnostics market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 4.05%. **Q: Which companies are considered key players in the US HIV diagnostics market?** A: Key players include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, and others. **Q: What were the market values for antibody tests in the US HIV diagnostics market in 2024?** A: The market value for antibody tests was $276.19 Million in 2024. **Q: How much is the market for nucleic acid tests projected to be in 2035?** A: The market for nucleic acid tests is projected to reach $438.59 Million by 2035. **Q: What segment had the highest market value in 2024 among end users?** A: Hospitals had the highest market value among end users at $276.19 Million in 2024. **Q: What is the projected market value for rapid testing technology by 2035?** A: The projected market value for rapid testing technology is $400.0 Million by 2035. **Q: What product type is expected to see significant growth in the US HIV diagnostics market?** A: Test kits are expected to see significant growth, with a market value of $276.19 Million in 2024. **Q: What was the market value for software products in the US HIV diagnostics market in 2024?** A: The market value for software products was $206.93 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-hiv-diagnostics-market-16658*